Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Marketsnovo nordiskanthropicdrug discoverysemaglutide

Novo Nordisk partners with Anthropic to use Claude in drug discovery

Novo already uses Claude to automate clinical trial report generation, cutting patient documentation timelines from months to minutes, according to the companies.

TR
By Tom Reyes · Markets Editor
Sep 18 15:57 ETSource: Drug Discovery News

The wire

  1. 01Novo Nordisk will test Anthropic's Claude models, including Claude Science, on targeted R&D problems and to strengthen its AI-driven software development, the companies said in a press release.
  2. 02The semaglutide maker is the largest peptide developer to formalise an AI research partnership, a signal for how incretin and peptide pipelines may be documented and screened.
  3. 03Financial terms and specific programmes were not disclosed, and the initial work is described as testing on selected problems rather than a committed discovery platform.

From the source

Novo Nordisk taps Anthropic's Claude to speed drug discovery

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.

Read at drugdiscoverynews.com
Source URL https://www.drugdiscoverynews.com/novo-nordisk-taps-anthropic-s-claude-to-speed-drug-discovery-17533